



William Dalmeida, M.S.

• Instructor of Neurology

Clinical Service Area

Neurology

Graduate School

M.S., University of Texas, San Antonio, Texas

Contact Information

William Dalmeida, M.S.
Department of Neurology
Baylor College of Medicine
One Baylor Plaza, MS NB302
Houston, Texas 77030

Tel: 713-798-5971

Email: williamd@bcm.edu

Journal Publications

1. Mandava P, Martini SR, Munoz M, Dalmeida W, Sarma AK, Anderson JA, et al. Hyperglycemia Worsens Outcome After rt-PA Primarily in the Large-Vessel Occlusive Stroke Subtype. *Transl Stroke Res.* 2014;5(4):519-25. [[View journal article](#)]
2. Mandava P, Dalmeida W, Anderson JA, Thiagarajan P, Fabian RH, Weir RU, et al. A pilot trial of low-dose intravenous abciximab and unfractionated heparin for acute ischemic stroke: Translating GP IIb/IIIa receptor inhibition to clinical practice. *Transl Stroke Res.* 2010;1(3):170-7. [[View journal article](#)]
3. Smith EM, Dalmeida W, Hughes TK. Signaling pathway-related gene expression in neuroimmunoregulation. *J Neuroimmunol.* 2004;147(1-2):138-40. [[View journal article](#)]
4. Gonzalez JM, Dalmeida W, Abramowitz J, Suki WN. Evidence for a fourth rat isoform of the plasma membrane calcium pump in the kidney. *Biochem Biophys Res Commun.* 1992;184(1):387-93. [[View journal article](#)]
5. Dalmeida W, Suki WN. Measurement of GFR with non-radioisotopic radio contrast agents. *Kidney Int.* 1988;34(5):725-8. [[View journal article](#)]
6. Rouse D, Dalmeida W, Williamson FC, Suki WN. Captopril inhibits the hydroosmotic effect of ADH in the cortical collecting tubule. *Kidney Int.* 1987;32(6):845-50. [[View journal article](#)]

Poster and Platform Presentations

1. Mandava P, Shah SD, Sarma AK, Dalmeida D, Kent TA. A pooled analysis indicates the promise and pitfalls of improving upon intravenous rt-PA for ischemic stroke. *Stroke.* 2014;45:AWP60.
2. Mandava P, Murthy SB, Dalmeida W, Hannawi Y, Wu EY, Kent TA. Generation of a pooled outcome model for traumatic brain injury to use for prediction of potential trial success. Presented at the Neurocritical Care Society (NCS), 11th Annual Meeting in Philadelphia, Penn. (Oct. 1-4, 2013).
3. Mandava P, Weir RU, Shah SD, Hannawi Y, Murthy SB, Anderson JA, et al. Extending the time window with low dose IV abciximab in acute non-lacunar stroke. *Stroke.* 2013;44(2_MeetingAbstracts):AWP68.
4. Mandava P, Weir RU, Shah SD, Hannawi Y, Murthy SB, Anderson JA, et al. Extending the time window with low dose IV abciximab in acute non-lacunar stroke. *Stroke.* 2013;44:AWP68.

5. Mandava P, Sarma AK, Dalmeida W, Anderson JA, Kent TA. Hyperglycemia is an independent risk factor for poor outcome after rtPA only in the large artery stroke subtype. *Cerebrovasc Dis.* 2011;31(suppl 2):255.
 6. Mandava P, Sarma AK, Dalmeida W, Anderson JA, Kent TA. Novel analysis methodology indicates extended window low-dose IV abciximab improves outcome. *Cerebrovasc Dis.* 2011;31(suppl 2):126.
 7. Mandava P, Munoz M, Dalmeida W, Sarma K, Brooks MA, Anderson J, et al. Hyperglycemia worsens outcome after rt-PA in the large artery stroke subtype. *Stroke.* 2011;42:e84.
 8. Mandava P, Munoz M, Sarma K, Brooks MA, Dalmeida W, Anderson J, et al. Gender and race interact to influence outcome of ischemic stroke after treatment with rt-PA. *Stroke.* 2011;42:e164.
 9. Mandava P, Anderson J, Dalmeida W, Kent TA. Platelet inhibition may explain results with abciximab in the treatment of acute ischemic stroke. *Cerebrovasc Dis.* 2009;27(Suppl 6):16.
- Kent TA, Fabian RH, Dalmeida W, Ruidong J, Dong JF. VWF pathway: A new animal model of lacunar stroke. *Stroke.* 2009;40:e219.